biostudies-literatureUnknown17Couetoux du Tertre MPersonalized Medicine Partnership for CancerFonds de Recherche du Québec - SantéPfizer Canada<h4>Background</h4>ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response duration or intrinsic/extrinsic therapeutic resistance. To further refine the application of personalized medicine in this indication, this study aimed to identify prognostic proteomic biomarkers in ALK fusion positive NSCLC patients to crizotinib.<h4>Methods</h4>Twenty-four patients with advanced NSCLC harboring ALK fusion were administered crizotinib in a phase IV trial which included blood sampling prior to treatment. Targeted proteomics of 327 proteins using MRM-MS was used to measurClinical proteomics5https://www.ebi.ac.uk/biostudies/studies/S-EPMC7006423biostudies-literatureDiscovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.PMC7006423Agulnik JGambaro KMcIntosh LHindie VBouchard NPottiez GWang HDiaconescu RCouetoux du Tertre MMcNamara SParent SMarques MCouture CBlais NPelsser VCroteau PBatist GBreton YAIzzi LCohen VHigenell VHoffert CCortes LSpatz ATremblay LfalseDiscovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.<h4>Background</h4>ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response duration or intrinsic/extrinsic therapeutic resistance. To further refine the application of personalized medicine in this indication, this study aimed to identify prognostic proteomic biomarkers in ALK fusion positive NSCLC patients to crizotinib.<h4>Methods</h4>Twenty-four patients with advanced NSCLC harboring ALK fusion were administered crizotinib in a phase IV trial which included blood sampling prior to treatment. Targeted proteomics of 327 proteins using MRM-MS was used to measur2020-01-01T00:00:00Z20202026-05-07T08:58:26.679Z2020-05-22T10:13:29ZS-EPMC70064233205523910.1186/s12014-020-9269-6